# Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

> **NCT05315687** · PHASE2 · WITHDRAWN · sponsor: **Emory University**

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Breast Carcinoma
- Metastatic Carcinoma in the Liver
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **DEVICE:** Y-90 SIR-Spheres
- **PROCEDURE:** Yttrium-90 Microsphere Radioembolization
- **OTHER:** Systemic Therapy

## Key facts

- **NCT ID:** NCT05315687
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-08-17
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is being closed because PI left Emory
- **Last updated:** 2024-01-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05315687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05315687, "Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT05315687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*